MicroRNAs in POI, DOR and POR
- PMID: 36840768
- DOI: 10.1007/s00404-023-06922-z
MicroRNAs in POI, DOR and POR
Abstract
Purpose: Premature ovarian insufficiency (POI) is a clinical syndrome defined by loss of ovarian activity before the age of 40 years. However, the etiology of approximately 90% patients remains unknown. Diminished ovarian reserve (DOR) and poor ovarian response (POR) are related to POI in clinic. The main purpose of this review was to evaluate the roles of microRNAs (miRNAs) in the pathogenesis and therapeutic potential for POI, DOR and POR.
Methods: A literature search was conducted using six databases (PubMed, EMBASE, Web of Science, Cochrane Library, CNKI and Wangfang Data) to obtain relevant studies.
Results: This review enlightens expression profiles and functional studies of miRNAs in ovarian insufficiency in animal models and humans. Functional studies emphasized the role of miRNAs in steroidogenesis, granulosa cell proliferation/apoptosis, autophagy and follicular development by regulating target genes in specific pathways, such as the PI3K/AKT/mTOR, TGFβ, MAPK and Hippo pathways. Differentially expressed circulating miRNAs provided novel biomarkers for diagnosis and prediction, such as miR-22-3p and miR-21. Moreover, exosomes derived from stem cells restored ovarian function through miRNAs in chemotherapy-induced POI models.
Conclusion: Differential miRNA expression profiles in patients and animal models uncovered the underlying mechanisms and biomarkers of ovarian insufficiency. Exosomal miRNAs can restore ovarian function against chemotherapy-induced POI, which needs further investigation to develop novel preventive and therapeutic strategies in clinical practice.
Keywords: Diminished ovarian reserve; Exosome; Poor ovarian response; Premature ovarian insufficiency; microRNAs.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
miRNA-122-5p in POI ovarian-derived exosomes promotes granulosa cell apoptosis by regulating BCL9.Cancer Med. 2022 Jun;11(12):2414-2426. doi: 10.1002/cam4.4615. Epub 2022 Mar 1. Cancer Med. 2022. PMID: 35229987 Free PMC article.
-
Specific expression profile of follicular fluid-derived exosomal microRNAs in patients with diminished ovarian reserve.BMC Med Genomics. 2023 Nov 30;16(1):308. doi: 10.1186/s12920-023-01756-9. BMC Med Genomics. 2023. PMID: 38037065 Free PMC article.
-
Adapted Exosomes for Addressing Chemotherapy-induced Premature Ovarian Insufficiency.Stem Cell Rev Rep. 2025 Apr;21(3):779-796. doi: 10.1007/s12015-024-10820-5. Epub 2025 Feb 8. Stem Cell Rev Rep. 2025. PMID: 39921838
-
Role of microRNAs in premature ovarian insufficiency.Reprod Biol Endocrinol. 2017 May 12;15(1):38. doi: 10.1186/s12958-017-0256-3. Reprod Biol Endocrinol. 2017. PMID: 28499456 Free PMC article. Review.
-
The Role of Noncoding RNA in the Pathophysiology and Treatment of Premature Ovarian Insufficiency.Int J Mol Sci. 2021 Aug 28;22(17):9336. doi: 10.3390/ijms22179336. Int J Mol Sci. 2021. PMID: 34502244 Free PMC article. Review.
Cited by
-
Analysis of single-cell RNA sequencing in human oocytes with diminished ovarian reserve uncovers mitochondrial dysregulation and translation deficiency.Reprod Biol Endocrinol. 2024 Nov 15;22(1):146. doi: 10.1186/s12958-024-01321-8. Reprod Biol Endocrinol. 2024. PMID: 39548561 Free PMC article.
-
The roles of MAPK signaling pathway in ovarian folliculogenesis.J Ovarian Res. 2025 Jul 14;18(1):152. doi: 10.1186/s13048-025-01737-9. J Ovarian Res. 2025. PMID: 40660328 Free PMC article. Review.
-
Biological therapies for premature ovarian insufficiency: what is the evidence?Front Reprod Health. 2023 Sep 7;5:1194575. doi: 10.3389/frph.2023.1194575. eCollection 2023. Front Reprod Health. 2023. PMID: 37744287 Free PMC article. Review.
-
Making a good egg: human oocyte health, aging, and in vitro development.Physiol Rev. 2023 Oct 1;103(4):2623-2677. doi: 10.1152/physrev.00032.2022. Epub 2023 May 12. Physiol Rev. 2023. PMID: 37171807 Free PMC article. Review.
-
Acupuncture Combined with Bushen-Jianpi Decoction Ameliorates the Ovarian Function of Diminished Ovarian Reserve Rats by Regulating Phosphoinositide 3-Kinase/AKT Signaling.Comb Chem High Throughput Screen. 2024;27(16):2402-2418. doi: 10.2174/0113862073264971231113061204. Comb Chem High Throughput Screen. 2024. PMID: 38178681
References
-
- European Society for Human, R., Embryology Guideline Group on, P. O. I., Webber L et al (2016) Eshre guideline: management of women with premature ovarian insufficiency. Hum Reprod 31(5):926–937. https://doi.org/10.1093/humrep/dew027 - DOI
-
- Golezar S, Ramezani Tehrani F, Khazaei S et al (2019) The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric 22(4):403–411. https://doi.org/10.1080/13697137.2019.1574738 - DOI - PubMed
-
- Nelson LM, Covington SN, Rebar RW (2005) An update: spontaneous premature ovarian failure is not an early menopause. Fertil Steril 83(5):1327–1332. https://doi.org/10.1016/j.fertnstert.2004.11.059 - DOI - PubMed
-
- Welt CK (2008) Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol (Oxf) 68(4):499–509. https://doi.org/10.1111/j.1365-2265.2007.03073.x - DOI - PubMed
-
- Pastore LM, Christianson MS, Stelling J et al (2018) Reproductive ovarian testing and the alphabet soup of diagnoses: dor, poi, pof, por, and for. J Assist Reprod Genet 35(1):17–23. https://doi.org/10.1007/s10815-017-1058-4 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous